CHMP Fast-Tracks BMS' Empliciti Nod
This article was originally published in Scrip
Bristol-Myers Squibb and AbbVie's novel treatment for multiple myeloma, Empliciti (elotuzumab), is set for EU approval after a speedy positive opinion from the CHMP. The development follows an earlier than expected approval at the US FDA last November for the same indication.
Register for our free email digests: